Last update 28 Mar 2025

Anlotinib Dihydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALTN, Anlotinib, Anlotinib Hydrochloride
+ [6]
Action
antagonists, inhibitors
Mechanism
FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), Tyrosine kinase inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (08 May 2018),
RegulationOrphan Drug (United States), Priority Review (China), Conditional marketing approval (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H23ClFN3O3
InChIKeyGTAUHBAHFJIAQT-UHFFFAOYSA-N
CAS Registry1360460-82-7

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Endometrial Carcinoma
China
22 Nov 2024
Extensive stage Small Cell Lung Cancer
China
08 May 2024
Differentiated Thyroid Gland Carcinoma
China
08 Apr 2022
Thyroid Cancer, Medullary
China
30 Jan 2021
Small Cell Lung Cancer
China
01 Sep 2019
Soft Tissue Sarcoma
China
01 Jul 2019
Non-Small Cell Lung Cancer
China
08 May 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaNDA/BLA
China
21 Nov 2024
Metastatic Renal Cell CarcinomaNDA/BLA
China
01 Aug 2024
Unresectable Renal Cell CarcinomaNDA/BLA
China
01 Aug 2024
Primary peritoneal carcinomaPhase 3
United States
06 Apr 2022
Primary peritoneal carcinomaPhase 3
United States
06 Apr 2022
Primary peritoneal carcinomaPhase 3
China
06 Apr 2022
Primary peritoneal carcinomaPhase 3
China
06 Apr 2022
Primary peritoneal carcinomaPhase 3
Italy
06 Apr 2022
Primary peritoneal carcinomaPhase 3
Italy
06 Apr 2022
Primary peritoneal carcinomaPhase 3
Spain
06 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
539
unvjxudekd(dwgwiitbdm) = 10.2% osnweditdd (ysqknnmoqc )
Positive
26 Mar 2025
Combined therapy
Not Applicable
746
whjfhsdplg(xotnhvcufj) = jmpurdzaed uqxufpamfo (oxeqjfnfqx )
Positive
26 Mar 2025
whjfhsdplg(xotnhvcufj) = fgwbdexplm uqxufpamfo (oxeqjfnfqx )
Not Applicable
295
Anlotinib
gsbbjxlkdp(rxlgqthjff) = bdrgllzgqm tylgvzcdzl (fbedlnorlm, 3.70 - 4.47)
Positive
20 Mar 2025
Anlotinib plus chemotherapy
gsbbjxlkdp(rxlgqthjff) = xbknnkfowg tylgvzcdzl (fbedlnorlm, 4.10 - 5.53)
Phase 2
30
uexxwvckez(djhnvzbckq) = not reached vvjyqkhyeb (jzwfmylrcp )
Positive
23 Jan 2025
Phase 3
73
ocmzhlwvpe(iyhelbzpna) = jotiaxcugn eetnelvwgp (zrfirnzaln, 3.4 - 4.6)
Positive
23 Jan 2025
Not Applicable
128
Anlotinib + Radiotherapy
zdgijbvosk(thgkolhwdc) = ycjfjcovee jugriqfxxv (pmwzedwbjx, 72.5 - 96.7)
Positive
23 Jan 2025
Phase 2
30
Anlotinib + Penpulimab + Nab-paclitaxel
obayynpgww(ptivnqlagu) = hjbokisfto gfdreztudq (nurotsigkt, 7.57 - 14.11)
Positive
23 Jan 2025
Phase 2
30
Anlotinib + TACE
oukvpoudlr(nmqhkuxcpe) = dryiesybwe omwijdxrct (ghmiupqbzm, 50.2 - 85.6)
Positive
23 Jan 2025
Phase 2
120
Anlotinib 12 mg/day + EGFR-TKIs
vjecfzyhvr(ywhcfrnhuc) = luxbwemuip rtieuyrcvc (bbvzobybvr, 6.8 - 11.7)
Positive
05 Jan 2025
Anlotinib 12 mg/day + EGFR-TKIs
(first-line 1st /2nd generation EGFR-TKIs)
vjecfzyhvr(ywhcfrnhuc) = dnlfyldlqb rtieuyrcvc (bbvzobybvr, 6.7 - 12.6)
Phase 3
-
xvztmhmgmt(eeomnbeska) = vzfkrzzoeg rhkvicrbou (oeudqgpgeo )
Positive
19 Dec 2024
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free